Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 3855-3861

  Liu, Minyan ^a   Guo, Lei ^b   Pei, Yu ^a   Li, Nan ^a   Jin, Mengmeng ^a   Ma, Lichao ^a   Liu, Yu ^a   Sun, Banruo ^a   Li, Chunlin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Bisphosphonates; Bone mineral density; Hip fracture; Osteoporosis

Indexed keywords

PLACEBO; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; DRUG EFFICACY; FEMALE; HIP FRACTURE; HUMAN; INCIDENCE; MALE; META ANALYSIS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SPINE FRACTURE;

EID: 84929380026     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22: 465-475.
2. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporosis Int 1997; 7: 407-413.
3. Khosla S, Lufkin EG, Hodgson SF, Fitzpatrick LA, Melton LJ III. Epidemiology and clinical features of osteoporosis in young individuals. Bone 1994; 15:551-5.
4. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16:87-116.
5. Demontiero O and Duque G. Once-yearly zoledronic acid in hip fracture prevention. ClinInterv Aging 2009; 4: 153-164.
6. Guggenbuhl P. Osteoporosis in males and females: Is there really a difference? Joint Bone Spine 2009; 76: 595-601.
7. Goncalves MJ, Rodrigues AM, Canhao H, Fon-seca JE. Osteoporosis: From bone biology to individual treatment decision. Acta Med Port 2013; 26: 445-455.
8. Piper PK, Gruntmanis U. Management of osteoporosis in the aging male: Focus on zoledronic acid. ClinInterv Aging 2009; 4: 289-303.
9. McClung M, Harris ST, Paul D. Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. Bisphosphonate therapy for osteoporosis: Benefits,risks, and drug holiday. Am J Med 2013; 126: 13-20.
10. Rakel A, Boucher A and Ste-Marie LG. Role of zoledronic acid in the preventionand treatment of osteoporosis. ClinInterv Aging 2011; 6: 89-99.
11. Rizzoli R. Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskel Dis 2010; 2: 3-16
12. Black DM, Delmas PD, Eastell R, Reid IR, Bo-onen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial.Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
13. Kimmel DB. Mechanism of action, pharmacokinetic, and pharmacodynamic profile, and clinical applications of nitrogen-containing bis-phosphonates. J Dent Res 2007; 86: 1022-1033.
14. Boonen S, Jean-Yves Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Riz-zoli R, Lipschitz S, Dimai HP, Witvrouw R, Eri-ksen E, Brixen K, Russo L, Claessens F, Papa-nastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Or-woll E. Fracture risk and zoledronic acid therapyin men with osteoporosis. N Engl J Med 2012; 367: 1714-23.
15. Lyles KW, Colón-Emeric CS, Magaziner JS, Ada-chi JD, Pieper CF, Mautalen C, Hyldstrup L, Re-cknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fracturesand mortality after hip fracture. N Engl J Med 2007; 357: 1799-809.
16. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporosis Int 2002; 13: 644-649.
17. Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW; HORIZON Recurrent Fracture Trial. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am GeriatrSoc 2011; 59: 2084-2090.
18. Yazici O, Aksoy S, Ucar O, Ozdemir N, Demir M, Sendur MA, Arik Z, Yaman S, Eren T, Uncu D, Zengin N. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis. Med Oncol 2013; 30: 609.
19. Arslan C, Aksoy S, Dizdar O, Dede DS, Harpu-tluoglu H, Altundag K. Zoledronic acid and atrial fibrillation in cancer patients. Support Care Cancer 2011; 19: 425-30.
20. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009; 4: e4720.
21. McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Os-teoporos Int 2012; 23: 267-76.
22. Watts NB. Long-term risks of bisphosphonate therapy. Arq Bras Endocrinol Metabol 2014; 58: 523-9.